Bayer AG News

May 21 - Fitch Ratings has revised the Outlook on Germany-based healthcare chemicals group Bayer AG's Long-term Issuer Default Rating to Positive from Stable and affirmed the IDR and senior unsecured ratings at 'A'-. The agency has also affirmed the Short-term IDR at 'F2' and Bayer's EUR1.3bn hybrid bond at 'BBB'. "The Positive Outlook reflects ... (more)

The Redwood City-based cancer drug developer, one of the most successful Bay Area biotech companies at raising venture capital over the past five years, said it will use proceeds of the IPO to advance its lead drug -- demcizumab, or OMP-21M18 -- and two other drugs into Phase II clinical trials and for programs with partners GlaxoSmithKline and ... (more)

The firm set a "hold" rating on the stock. A number of other analysts have also recently weighed in on BAYRY.

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.India's patents chief ruled in March the price Bayer charged for the drug, Nexavar, was "exorbitant" and ordered the firm to give a so-called "compulsory ... (more)

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Tuesday.

The company's announcement comes after chatter emerged of Bayer AG making a bid for the company at $32 per Warner Chilcott share.

The ratings on Germany-based pharmaceuticals, polymers, and agrochemicals conglomerate Bayer AG reflect Standard & Poor's Ratings Services' view of the group's strong business risk profile.